Previous 10 | Next 10 |
Mesoblast (MESO) -31% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19.Wunong Net Technology Company (WNW) -18%.Applied DNA Sciences (APDN) -16% on Q4 earnings release.Takung Art (TKAT) -14%.Virgin Galactic Holdings (SPCE) -11%&...
Mesoblast (MESO) slumps 32% after-hours after an update on remestemcel-L trial in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome ((ARDS)) due to COVID-19.Data Safety Monitoring Board ((DSMB)) performed a third interim analysis on the trial&...
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients...
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection aft...
Shares of Mesoblast Limited (NASDAQ: MESO) were tumbling 19.6% lower as of 12:41 p.m. EST on Tuesday. The big drop came after the company announced Monday evening that its off-the-shelf cell therapy candidate rexlemestrocel-L (Revascor) failed to meet the primary endpoint of a late-...
Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...
Gainers: Anchiano Therapeutics ANCN +173%, Prevail Therapeutics PRVL +84%, BioCardia (BCDA) +40%, Solid Biosciences (SLDB) +37%, OncoCyte OCX +32%.Losers: Mirum Pharmaceuticals (MIRM) -21%, Mesoblast (MESO) -18%, Rubius Therapeutics ...
Apartment Investment and Management (AIV) -84% after spinoff of Apartment Income REIT closes.CooTek (Cayman) (CTK) -13% on Q3 earnings release.Mirum Pharmaceuticals (MIRM) -19% after prices equity offering at $20.Mesoblast (MESO) -15% after it ...
Mesoblast (MESO) slips 10% after-hours after announcing top-line results from the landmark DREAM-HF Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR) in 537 patients with advanced chronic heart failure. Over a mean 30 months of follow-up, patients wi...
Gainers: [[MDWD]] +19.5%. [[KZR]] +14.3%. [[PQG]] +9%. [[GOSS]] +4%. [[RC]] +2.6%.Losers: [[MESO]] -7.6%. [[CELP]] -5.3%. [[GDS]] -5.1%. [[EAF]] -4.2%. [[RUBY]] -4%. For further details see: MESO, EAF, RC and MDWD among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...